CapitaLand (OTCMKTS:CLLDY) versus Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Critical Review

Dividends

CapitaLand pays an annual dividend of $0.12 per share and has a dividend yield of 1.9%. Shionogi & Co., Ltd. pays an annual dividend of $0.11 per share and has a dividend yield of 1.6%. Shionogi & Co., Ltd. pays out 18.6% of its earnings in the form of a dividend.

Profitability

This table compares CapitaLand and Shionogi & Co., Ltd.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CapitaLand	N/A	N/A	N/A
Shionogi & Co., Ltd.	35.53%	11.95%	10.56%

Valuation and Earnings

This table compares CapitaLand and Shionogi & Co., Ltd.”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapitaLand	$4.74 billion	3.41	-$1.14 billion	N/A	N/A
Shionogi & Co., Ltd.	$3.01 billion	3.97	$1.12 billion	$0.59	11.92

Shionogi & Co., Ltd. has lower revenue, but higher earnings than CapitaLand.

Volatility and Risk

CapitaLand has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Shionogi & Co., Ltd. has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.

Insider & Institutional Ownership

1.9% of Shionogi & Co., Ltd. shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Shionogi & Co., Ltd. beats CapitaLand on 6 of the 10 factors compared between the two stocks.

About CapitaLand

CapitaLand is one of Asia’s largest real estate companies headquartered and listed in Singapore. The company leverages its significant asset base, design and development capabilities, active capital management strategies, and extensive market network and operational capabilities to develop high-quality real estate products and services. Its diversified global real estate portfolio includes integrated developments, shopping malls, serviced residences, offices and homes. The Group focuses on Singapore and China as our core markets, while it continues to expand in markets such as Vietnam and Indonesia. The company also has one of the largest real estate fund management businesses with assets located in Asia.

About Shionogi & Co., Ltd.

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.